NeoGenomics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
NeoGenomics, Inc. (NEO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$35.30 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2022-08-09
- NeoGenomics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2022-06-30 was -$35.30M, a 145.60% decline year-over-year.
- NeoGenomics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was -$20.35M, a 548.98% decline year-over-year.
- NeoGenomics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was $77.42M.
- NeoGenomics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2020-09-30 was $4.53M, a 111.48% increase year-over-year.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|---|
| 2022-06-30 | -$35.30M 10-Q · filed 2022-08-09 | -$84.71M 10-Q · filed 2022-08-09 | |
| 2021-09-30 | -$20.35M 10-Q · filed 2021-11-04 | $57.08M derived: sum of 2 quarters · filed 2022-08-09 | $33.41M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $77.42M 10-Q · filed 2022-08-09 | $56.76M 10-Q · filed 2022-08-09 | |
| 2020-09-30 | $4.53M 10-Q · filed 2021-11-04 | -$2.29M derived: sum of 2 quarters · filed 2021-11-04 | -$11.24M 10-Q · filed 2021-11-04 |
| 2020-06-30 | -$6.82M 10-Q · filed 2021-08-09 | -$13.80M 10-Q · filed 2021-08-09 | |
| 2019-09-30 | $2.14M 10-Q · filed 2020-10-29 | $1.71M 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |